Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin-supported melphalan dose escalation before autologous transplant in multiple myeloma
ACTRN12606000433505Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Nov 2006
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palifermin and melphalan in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Maximum tolerated dose of intravenous melphalan in combination with palifermin. Planned start Nov 2006; status: not yet recruiting.
02
Drugs
paliferminmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12606000433505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000433505.